本文字数：1229，阅读时长大约2分钟 作者 | 第一财经 程程 据央视新闻报道，当地时间7月8日，美国总统特朗普在内阁会议上表示，"我们很快将在医药领域宣 布一些重要举措"。 特朗普称："我们会给相关企业大约一年到一年半的时间来调整，之后他们将面临关税。"他补充 说："如果他们必须将药品和其他相关产品进口到国内，关税将高达200%。" 值得注意的是，投资者似乎尚未认真对待这一关税威胁。当地时间7月9日，许多欧洲制药公司的股 价几乎没有变化，追踪印度制药股的标普BSE医疗保健指数9日收盘时大致持平。 巴克莱银行分析师菲尔德（Emily Field）表示，投资者对最新的医药关税威胁不以为然，认为这只 是"空谈"，"特朗普总是退缩（TACO）交易的观念仍然盛行。" 2025.07. 11 瑞银制药业分析师韦斯顿（Matt Weston）表示，考虑到获得监管部门批准和建设高科技制造工厂所 需的时间，18个月的时间不足以将制造业转移到美国。他表示："我们通常认为将商业规模的制造转 移到新工厂需要4年-5年的时间。" 韦斯顿称，向美国出口高价成品药的公司受到的影响最大。但他也表示，欧洲制药公司通常不会这样 做，许多公司 ...

Group 1 - The core viewpoint of the news highlights the strong support from the government for the development of innovative drugs, as evidenced by the release of 16 supportive policies by the National Healthcare Security Administration and the Health Commission [1] - The approval of Shuwotini by Dize Pharmaceutical as the first domestically developed EGFR exon 20 insertion NSCLC drug to be approved in the U.S. underscores the international competitiveness of domestic innovative drugs [1] - The biopharmaceutical sector has shown strong performance, significantly outperforming the broader market index, with a year-to-date increase of 7.09% and a recent weekly increase of 4.40% [1] Group 2 - The biopharmaceutical ETF tracks the CS Biomedicine Index, which includes listed companies involved in biotechnology and medical devices, reflecting the overall performance of the biopharmaceutical sector [2] - The index covers multiple sub-sectors, showcasing high growth and innovation characteristics within the biopharmaceutical and medical device industries [2]

截至2025年7月11日 09:34，恒生医疗保健指数(HSHCI)强势上涨1.64%，成分股药明康德(02359)上涨 9.84%，同源康医药-B(02410)上涨7.22%，药明合联(02268)上涨6.73%，博安生物(06955)，药明生物 (02269)等个股跟涨。恒生医疗ETF(513060)上涨1.04%，最新价报0.58元。拉长时间看，截至2025年7月 10日，恒生医疗ETF近2周累计上涨3.21%。 流动性方面，恒生医疗ETF盘中换手2.29%，成交1.85亿元。拉长时间看，截至7月10日，恒生医疗ETF 近1月日均成交20.92亿元，排名可比基金第一。 消息面上，7月10日晚间，药明康德发布业绩预告，预计上半年经调整归母净利润约人民币63.15亿元， 同比增长约44.43%；预计上半年实现归属于本公司股东的净利润约人民币85.61亿元，同比增长约 101.92%，其中包含了出售联营公司部分股权所获得的投资收益；本期基本每股收益预计约人民币3.01 元/股，同比增长约106.16%。业绩增长得益于其 "一体化、端到端" 业务模式，以及新能力拓展和产能 建设等。 广发证券认为，我国创新药发展 ...

Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index up by 0.24%, the Shenzhen Component Index up by 0.12%, and the ChiNext Index up by 0.01% as of 9:44 AM on July 11 [1] Sector Performance - The brokerage sector was strong, with Zhongyin Securities achieving two consecutive trading limits. The rare earth permanent magnet concept continued to rise, with Jingyuntong hitting the daily limit. The stablecoin concept remained active, with multiple stocks like Guoao Technology reaching the daily limit. The shipbuilding sector rebounded, with China Shipbuilding rising over 4%. The real estate sector remained active, with Shibei Gaoxin hitting the daily limit. The photovoltaic sector showed repeated activity, with Guosheng Technology achieving three consecutive trading limits. The innovative drug sector also strengthened, with Kangchen Pharmaceutical achieving two consecutive trading limits. Other sectors such as precious metals, aquaculture, and engineering machinery also saw gains. In contrast, sectors like diversified finance, gaming, consumer electronics, and education experienced notable declines [2] Real Estate Sector - The real estate stocks saw renewed strength, with Shibei Gaoxin, Tianbao Infrastructure, and Greenland Holdings hitting the daily limit, while companies like Yudai Development and Huaxia Happiness also saw gains. This was supported by the State Council's issuance of an opinion to enhance the mechanism for efficiently handling key matters, encouraging local governments to focus on high-frequency issues and expand application scenarios in various fields [4] Rare Earth Sector - The rare earth sector saw multiple stocks perform well, with Zhongke Magnetic Materials rising over 10% and Jingyuntong hitting the daily limit. The price of rare earth concentrate was raised by Baogang Group and Northern Rare Earth, increasing by 1.51% compared to the previous quarter. This marks the fourth consecutive quarter of price increases since Q4 of last year. Additionally, overnight gains in U.S. rare earth stocks, such as MP Materials rising by 50.62%, were noted [6] Institutional Insights - Dongguan Securities expressed a cautious bullish outlook for the market, noting that the domestic economy continues to operate steadily, with the central bank's second-quarter monetary policy meeting indicating an improving economic outlook. However, external factors such as U.S. tariffs on specific industries may impact market sentiment [8] - Guoxin Securities highlighted that while market risk appetite has increased, the profit-making effect remains relatively dispersed. They expect the market center to remain optimistic as fundamental expectations improve [9] - Ping An Fund maintained a long-term bullish perspective, anticipating strong performance in sectors like military and new energy as the semi-annual report disclosure period approaches. They noted potential tactical adjustments in the short term but emphasized ongoing structural opportunities in technology and resource sectors [10]

Core Insights - The A-share market concluded the first half of 2025 with a structural market trend, showing significant performance divergence among public funds, with an average return of 4.13% and over 87% of funds achieving positive returns [2][3] - The top-performing funds were primarily focused on the pharmaceutical and biotechnology sectors, while some funds heavily invested in new energy and artificial intelligence themes faced performance challenges [2][3] Fund Performance Overview - The top fund, Huatai Hong Kong Advantage Selection A, achieved a remarkable return of 86.48%, while the bottom fund, Qianhai Kaiyuan Artificial Intelligence A, recorded a loss of -20.57%, resulting in a performance gap of 107 percentage points [2][3][5] - The top 30 funds exhibited three notable characteristics: a strong rise of North Exchange theme funds, widespread success of pharmaceutical theme funds, and robust performance of Hong Kong Stock Connect innovative drug ETFs [3][5] Top 30 Funds Summary - The top three funds were: 1. Huatai Hong Kong Advantage Selection A (86.48%) 2. CITIC Construction Investment North Exchange Selection Two-Year Open A (82.45%) 3. Great Wall Pharmaceutical Industry Selection A (75.18%) [4][5] - The North Exchange 50 Index rose approximately 39.45% in the first half of the year, with related theme funds dominating the top ten performance rankings [3][5] Bottom 30 Funds Summary - The bottom fund, Qianhai Kaiyuan Artificial Intelligence A, had a return of -20.57%, with most underperforming funds being mixed and stock funds, showing losses between -12.43% and -20.57% [6][7] - The underperforming funds were heavily concentrated in technology and AI sectors, which faced significant downturns, contrasting with the strong performance of healthcare and innovative drug sectors in top-performing funds [8][9] Market Outlook - The A-share market is expected to present a "volatile upward" trend in the second half of 2025, supported by a series of domestic growth policies and monetary easing [11][12] - Investment strategies should balance high-growth sectors with stable dividend assets, focusing on innovative drugs and technology while considering potential external uncertainties [12]

A股创新药概念早盘涨幅居前，常山药业涨超16%，康辰药业涨停，联环药业涨超9%，广生堂、立方制 药、华北制药等个股跟涨。日前国家医保局公布工作方案，今年将首次制定商保创新药目录。 ...

Core Viewpoint - The innovative drug concept continues to show strong performance, with significant stock price increases for companies such as Boteng Co. and Changshan Pharmaceutical, which rose over 15% [1] Group 1: Stock Performance - Boteng Co. and Changshan Pharmaceutical saw stock increases of over 15% [1] - WuXi AppTec experienced a nearly 9% rise [1] - Other companies like Kylin Pharmaceutical, Guangsheng Pharmaceutical, and Yifang Bio also saw stock increases of over 5% [1] Group 2: Policy Announcement - On July 10, the National Healthcare Security Administration announced the adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs, as well as the Commercial Health Insurance Innovative Drug Catalog [1] - The plan specifies that the adjustments to the basic medical insurance drug catalog and the establishment of the commercial health insurance innovative drug catalog will occur simultaneously in 2025 [1]

恒生指数盘初涨幅扩大至1%，恒生科技指数现涨1.06%；生物医药、创新药、医药外包等大医药概念走 强；芯片股连日上涨，中资券商股延续涨势；国泰君安国际(01788.HK)涨超7%，凯莱英(06821.HK)涨 超16%，昨日人气个股普星能量(00090.HK)涨超22%。 ...

港股创新药概早盘大幅走强，药明康德(02359.HK)报盈喜涨超10%，药明合联(02268.HK)涨超7%，博安 生物(06955.HK)、恒瑞医药(01276.HK)等个股跟涨。 ...

2025 年 07 月 11 日 双融日报 --鑫融讯 分析师：万蓉 S1050511020001 wanrong@cfsc.com.cn 市场情绪：76 分（较热） 最近一年大盘走势 资料来源：Wind，华鑫证券研究 -15 -10 -5 0 5 10 15 20 25 (%) 沪深300 相关研究 ▌ 华鑫市场情绪温度指标：（较热） 华鑫市场情绪温度指标显示，昨日市场情绪综合评分为 76 分，市场情绪处于"较热"。历史市场情绪趋势变化可参 考图表 1。 ▌ 热点主题追踪 今日热点主题：数据、跨境支付、创新药 1、数据主题：据《央视新闻》报道，为了破解数据流通 交易效率不高的难题，国家数据局、国家市场监督管理总局 首次推出数据流通交易便利化举措，发布数据流通交易合同 示范文本，为有需要的经营主体提供参考。有关企业反馈， 合同应用将大幅降低数据流通交易的协商成本，预计可提升 30%的效率。相关 标 的：奥飞数据（ 300738）、易华录 （300212） 2、跨境支付主题：7 月 4 日，央行发布《人民币跨境支 付系统业务规则（征求意见稿）》，向社会公开征求意见至 8 月 3 日。此次修订简化境外机构参与条件 ...